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1. Introduction 
The immune system is confronted with antigens and proteins that have not been 
previously encountered by the body. Dendritic cells are professional antigen-presenting 
cells and play a key role in the induction of these immune responses (Banchereau and 
Steinman, 1998; Lanzavecchia and Sallustoa, 2001; Mellman and Steinman, 2001). 
Dendritic cells orchestrate a variety of immune responses by stimulating the 
differentiation of naïve CD4+ T cells into helper T effectors such as Th1, Th2, Treg cells 
and Th17 cells and several factors determine the direction of T cell polarization 
(Romagnani 1994; Kuchroo et al. 1995; Lederer et al. 1996; Tao et al. 1997; Forster et al. 
1999; Lezz et al. 1999; Tanaka et al. 2000; O’gara, 20001; Steinman and Dhodapkar, 2001). 
The cytokine profile present during an immune reaction is an important element in 
directing the response to T cell polarization. A maturation process, IL-12 production, the 
up-regulation of MHC and costimulatory molecules, is critical for initiation of primary T 
cell response. Th1 responses predominate in organ-specific autoimmune disorders, acute 
allograft rejection and in some chronic inflammatory disorders (Trinchieri and Scott, 
1994). Although different dendritic cells subsets may have some intrinsic potential to 
preferentially induce Th1, Th2, Treg cells or Th17 cells, dendritic cells also display 
considerable functional plasticity in response to signals from microbes and the local 
microenvironment (Steinman, 2007). Numerous stimuli can mediate dendritic cells 
maturation, the best characterized being Toll-like receptor (TLR) ligands and signals such 
as CD40L delivered by T cells and innate lymphocytes (Hermann et al. 1998). TLRs are 
expressed mainly on macrophages and dendritic cells, triggering results in the 
development of effector dendritic cells that promote Th1 responses (Okamoto and Sato, 
2003). Recently, several studies proposed the significance of TLR signaling in the 
induction of anti-cancer immunity. In addition to their essential role in T cell priming, 
dendritic cells are also involved in innate immunity through the production of cytokines 
and the activation of NK or NKT cells. Thus, dendritic cells play a pivotal role in 
orchestrating the immune response. 
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The hooks of Uncaria sp. are contained in Choto-san as the main component herb. Choto-san 
has been used for hypertension and dementia, and well used as an important of many 
Chinese prescriptions in China, Korea and Japan. Uncarinic acid (URC) and Ursolic acid are 
isolated from Uncaria rhynchophylla and phytochemically classified as triterpene. A number 
of alkaloids have been reported as antihypertensive principles from the genus Uncaria. URC 
showed potent inhibitory activity against phospholipase C1 and inhibited the growth of 
cancer cells at high doses (Lee et al. 2000). Ursolic acid augments the inhibitory effects of 
anticancer drugs on growth of human tumor cells and triggers apoptosis in cancer cells. 
Triterpene have been identified as a unique class of natural products possessing diverse 
biological activities. Terpenes also contain pharmacologically active substance. Recently, we 
have reported that numerous terpenes induce the differentiation of dendritic cells from 
human monocytes, and drive Th1 and Th2 differentiation (Takei et al. 2005, 2007, 2008). For 
immunotherapeutic applications, it appears crucial to identify factors that might affect the 
differentiation and function of dendritic cells. Although various terpene compounds have 
pharmacological activity, relatively little is known in regards to the influences URC and 
Ursolic acid exert on the initiation of specific immune response at the level of dendritic cells. 
Therefore, to further understand the cellular basis of immunological with abnormalities 
associated URC and Ursolic acid exposure, we investigated the ability of URC and Ursolic 
acid on human dendritic cells differentiation (surface molecule), function (cytokines 
production) and their activation (NF-B translocation to the nucleus) in detail. Some terpene 
compounds may lead to the development of effective immunotherapy for cancer. 
2. Monocyte-derived dendritic cells phenotype 
In order to study the direct effect of URC and Ursolic acid on the function of human 
monocyte dendritic cells, immature monocyte-derived dendritic cells were exposed to URC 
and Ursolic acid, and phenotypic and functional dendritic cells maturation was analyzed. 
URC and Ursolic acid were prepared as previously described (Lee et al. 2000). The purity of 
URC and Ursolic acid was > 99%. URC and Ursolic acid was dissolved in dimethyl 
sulfoxide. The concentration of dimethyl sulfoxide in the culture medium was 0.1%, which 
had no effect on the culture and the production of cytokines under the conditions used in 
this study. The endotoxin in URC and Ursolic acid was removed using End Trap 5/1 (Profos 
AG, Regensburg, Germany). Endotoxin levels in URC and Ursolic acid were below 0.05 
EU/ml. Human monocytes were cultured with GM-CSF and IL-4 for 6 days under standard 
conditions, followed by an additional 2 days in the presence of URC and Ursolic acid. Under 
these conditions, we found that CD1a, CD38, CD40, CD54, CD80, CD83, CD86 and HLA-DR 
expression levels on URC-primed dendritic cells and Ursolic acid-primed dendritic cells 
were slightly enhanced. Typical data of phenotypes are shown in Fig.1. The viability of cells 
treated with a concentration of 0.1 M URC and 1.0 M Ursolic acid was >95%. URC and 
Ursolic acid were kept at 0.1 or 1.0 M, respectively, for subsequent experiments. As a 
positive control, human monocytes were cultured with GM-CSF and IL-4 for 6 days, 
followed by another 2 days in the presence of LPS or TNF-. LPS and TNF- are a known 
dendritic cells maturation-enhancing factors. The expression of co-stimulatory molecules 
and maturation markers including CD38, CD80, CD83, CD86 and HLA-DR on LPS (100 
ng/ml)-primed dendritic cells or TNF- (25 ng/ml)-primed dendritic cells was higher than 
URC-primed dendritic cells and Ursolic acid-primed dendritic cells (Fig. 1). Immature 
dendritic cells (with medium) were generated by cultivating human monocytes with GM-
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CSF and IL-4 for 8 days served as a control. The expression level of CD14 as expressed by 
MFI on day 8 was found to be low or undetectable in some samples. Type 1 interferons’ are 
(IFNs) are important in immune responses against tumors. When human monocyte-derived 
dendritic cells were stimulated with URC in the presence of IFN-(100 ng/ml), the 
expression of co-stimulatory molecules and maturation markers on URC-primed dendritic 
cells was significantly increased by IFN- administration (data not shown). Immature 
dendritic cells are efficient in capturing Ag and have a high level of endocytosis. To 
determine whether mechanisms of Ag capture could also be modulated by URC and Ursolic 
acid, the endocytic activity was measured in immature dendritic cells, URC-, Ursolic acid-, 
LPS- and TNF--primed dendritic cells. FITC-dextran uptake mediated by URC-, Ursolic 
acid-, LPS- and TNF--primed dendritic cells was lower than immature dendritic cells (data 
not shown). These results suggested that dendritic cells differentiated by URC and Ursolic 
acid have down-regulated their endocytic capacity. 
 
Fig. 1. Phenotype of dendritic cells differentiated with URC, Ursolic acid, LPS or TNF-
Dendritic cells were generated by stimulating immature dendritic cells with URC  
(0.1 M), Ursolic acid (1 M), LPS (100 ng/ml) or TNF- (25 ng/ml) and then were stained 
with FITC-conjugated Ab or PE-conjugated Ab against CD1a, CD38, CD40, CD54, CD80, 
CD83, CD86, HLA-DR and CCR-7 as described previously (Takei et al. 2005). Antibodies 
were overlayed with their isotype control. Data are one experiment representative of four 
independent experiments.  
2.1 Immunostimulatory capacity in an allogeneic mixed lymphocyte reaction 
The ability to induce allogeneic T cell proliferation is a functional hallmark of dendritic cells 
in vitro. Change in the surface marker expression is also reflected at a functional level, when 
analyzing the allostimulatory capacity of dendritic cells in an allogeneic mixed lymphocyte 
reaction. Efficiency in an allogeneic mixed lymphocyte reaction for URC-primed dendritic 
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cells and Ursolic acid-primed dendritic cells were enhanced in a dose-dependent manner 
(data not shown). URC-, Ursolic acid- and LPS-primed dendritic cells was demonstrated a 
higher stimulatory efficiency in an allogeneic mixed lymphocyte reaction than immature 
dendritic cells and TNF--primed dendritic cells (Fig. 2). Simultaneous dendritic cells 
stimulation with URC in the presence of IFN-(100 ng/ml) appeared to enhance this effect 
(data not shown). URC–primed dendritic cells and Ursolic acid-primed dendritic cells 
resulted in enhancement of T cell proliferation, indicating that URC and Ursolic acid 
potentiate the Ag-presenting activity of dendritic cells in an allogeneic mixed lymphocyte 
reaction.  
 
Fig. 2. Allogeneic T cell stimulatory capacity of dendritic cells differentiated with URC, 
Ursolic acid, LPS or TNF-. Naïve T cells were co-cultured with gradually increasing doses 
of dendritic cells and on day 5, 3H methylthymidine was added 16 h. before measurement 
of the proliferation responses. Data are the mean cpm  S.E.M. of five independent 
experiments. *P< 0.05 compared with immature dendritic cells. 
2.2 IL-10 and IL-12p70 release by activated dendritic cells 
Since dendritic cells serve as the professional antigen-presenting cells and their secretion of 
immunoregulatory and proinflammatory cytokines plays a crucial role in T cell priming, we 
then investigated whether cytokine production by human monocyte-derived dendritic cells 
was affected by treatment with URC and Ursolic acid. IL-10 is a pleiotropic cytokine known 
to have inhibitory effects on the accessory functions of dendritic cells and appears to play a 
central role in preventing overly pathological Th1 or Th2 responses in a variety of settings. 
In contrast, the level of IL-12 production by myeloid dendritic cells during activation of 
naïve T cells is a major factor driving the development of Th1 cells. Therefore, we measured 
IL-10 and IL-12p70 productions in immature dendritic cells (with medium) and in dendritic 
cells matured for 2 days in the presence of the above factors after stimulation by CD40 L-
transfected for 24 h. Measurements of cytokines production were determined by ELISA kit. 
Major enhancements of IL-12p70 production were caused by URC and Ursolic acid, and this 
production was dose-dependent manner (Fig.3A and data not shown). Dendritic cells 
matured with URC in the presence of IFN- (100 ng/ml) produced even higher levels of IL-
12p70 upon CD40 ligation (data not shown). In contrast, the production of IL-10 by URC-, 
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Ursolic acid-, LPS- or TNF--primed dendritic cells was low. On the other hand, the 
production of IL-10 and IL-12p70 by immature dendritic cells was low (Fig.3A and B).  
 
Fig. 3. The production of IL-12p70 by URC-primed dendritic cells and Ursolic acid-primed 
dendritic cells was inhibited by anti-TLR2 mAb and anti-TLR4 mAb. Dendritic cells were 
generated by stimulating immature dendritic cells with URC (0.1 M), Ursolic acid (1 M), 
LPS (100 ng/ml) or TNF- (25 ng/ml). Cells (4x104 cells/well) were stimulated with the 
CD40 L-transfected J558 cells (5x104 cell/well) for 24 h., the production of IL-12p70 (A and 
IL-10 (B) was measured by ELISA in culture supernatants. iDC: immature dendritic cells. 
Data are the mean  S.E.M. of five independent experiments. *P< 0.05 compared without 
mAb.  
2.2.1 Effects of anti-TLR 2 mAb and anti-TLR4 mAb on cytokine production by URC-
primed dendritic cells and Ursolic acid-primed dendritic cells 
Dendritic cells activation is mediated by a member of the Toll-like family of receptor and 
TLR agonists are potent activators of innate immune responses. TLR signaling results in the 
differentiation of dendritic cells from human monocytes which, in turn, prime an effective 
Th1 response as recent studies that focused on the molecular mechanisms underlying 
Th1/Th2 development. We evaluated the role for TLRs in the development of Th1 cells in 
naïve T cells co-cultured with URC and Ursolic acid. Before stimulation with URC and 
Ursolic acid, monocyte-derived dendritic cells were incubated in the presence of the TLR2 
mAb (10 g/ml), TLR4 mAb (10 g/ml) or an isotype control (IgG1). Then, dendritic cells 
were stimulated with CD40 L –transfected J558 cells for 24 h. The anti-TLR2 mAb and anti-
TLR4 mAb inhibited the production of IL-12p70 by URC-primed dendritic cells and Ursolic 
acid-primed dendritic cells by50-70% (Fig.3A). On the other hand, the production of IL-
12p70 by LPS-primed dendrite cells was inhibited by the anti-TLR4 mAb, whereas the anti-
TLR2 mAb was not inhibited the production of IL-12p70 by LPS-primed dendritic (Fig.3A). 
mAb did not inhibit the the production of IL-10 induced by URC-, Ursolic acid- and LPS-
primed dendritic cells (Fig.3B). In contrast, the response to TNF- was not influenced in the 
presence of the anti-TLR2 mAb and anti-TLR4 mAb did not inhibit (Fig.3A and B). The 
production of IL-12p70 by URC in combination with IFN- was not influenced by adding, 
whereas the production of IL-10 was not influenced by the anti-TLR4 mAb (data not 
shown). The production of IL-10 and IL-12p70 by URC-, Ursolic acid-, LPS- or TNF--
primed dendritic cells was not influenced when IgG1 was added instead of anti-TLR 2 mAb 
or anti-TLR4 mAb (Fig.3A and B).  
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It was left undermined whether TLR2 and TLR4 express on URC-primed dendritic cells and 
Ursolic acid-primed dendritic cells. To address this question, we examined expression of 
TLR2 and TLR4 on URC-primed dendritic cells and Ursolic acid-primed dendritic cells. 
Total cellular RNA was extracted using RNeasy Mini kits (Qiagen GmbH, Germany), 
according to manufacturer’s recommendations. Using RT-PCR, we found that URC-primed 
dendritic cells and Ursolic acid-primed dendritic cells expressed significant levels of mRNA 
coding for both TLR2 and TLR4 (data not shown). These data are compatible with URC and 
Ursolic acid activation of dendritic cells via TLRs.  
2.2.2 NF-B activation and TLR expression 
Dendritic cells activation and maturation driven by TLR agonist such as LPS has been 
clearly associated to NF-B activation. To determine whether URC and Ursolic acid uses 
similar activation pathways, we monitored thier ability to activate of the NF-B 
translocation into the nucleus. EMES was performed with the Gel Shift assay system 
(Promega, El, USA). Dendritic cells were cultured in the presence of URC and Ursolic acid 
for 30 min, 1 h. and 2 h., and nuclear extracts were analyzed for NF-B content. As shown in 
Fig.4A, URC was able to induce NF-B translocation and activation. Similar results were 
obtained with Ursolic acid-primed dendritic cells and LPS-primed dendritic cells (data not 
shown and Fig.4A). The expression of TLR2 and TLR4 on monocytes, immature dendritic 
cells, URC-, Ursolic acid- and LPS-primed dendritic cells was further analyzed by real-time 
quantitative RT-PCR, because of their different selective expression on dendritic cells. 
Monocytes and immature dendritic cells expressed the highest levels of TLR2 and TLR4 on 
the cell population examined. mRNA expression of these two receptors was dramatically 
down-regulated upon differentiation of monocytes into dendritic cells after 8 days of culture 
with GM-CSF, IL-4 plus LPS, URC and Ursolic acid (Fig.4B and C). URC-primed dendritic 
cells and Ursolic acid-primed dendritic cells expressed considerable levels of TLR2 and 
TLR4. In URC-primed dendritic cells and Ursolic acid-primed dendritic cells, TLR4 
expression seemed to be more prominent than TLR2 (Fig.4B and C). The expression of TLR4 
on URC-primed dendritic cells and Ursolic acid-primed dendritic cells was higher than that 
of LPS-primed dendritic cells. Interestingly, we found that upon URC, Ursolic acid and LPS 
stimulation, mRNA expression of TLR2 and TLR4 was down-regulated with overall mRNA 
transcript detection levels being lower than in immature dendritic cells. It has been reported 
that monocyte-derived immature dendritic cells down-regulate TLR2 and TLR4 upon 
maturation with the corresponding cognate ligand LPS (Ismaili et al. 2002). Our 
experimental data support their observation showing that LPS in human dendritic cells and 
monocytes express different mRNA TLR transcripts. One might speculate that URC- and 
Ursolic acid-induced regulation of TLR2 and TLR4 expression may be involved in positively 
or negatively modulating the recognition of URC and Ursolic acid motifs by TLR2 and 
TLR4. URC, Ursolic acid and LPS were, in part, involved in down-regulation of human. 
These data suggest that URC and Ursolic acid might activate by dendritic cells via a TLR4 
and/or TLR2 signaling. Our experiments showed that common pathways are activated by 
URC, Ursolic acid and LPS, as they modulate TLR expression. An important 
immunomodulatory property of TLR agonists is their capacity to enhance IL-12 production 
of dendritic cells and other innate immune cells. TLR signaling frequently generate dendritic 
cells and enhances the production of IL-12, a major Th-1-inducing cytokine (Okamoto and 
Sato, 2003). It suggests that dendritic cells activated by TLR2 and TLR4 stimulation may 
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induce T cell differentiation toward Th1 by presenting antigens to T cells while promoting a 
Th1-leading situation in the local environment. Ability to promote Th1-type responses plays 
a key protective role in immunity to tumor. Interestingly, anti-TLR2 mAb and anti-TLR4 
mAb enhanced the production of IL-10 by URC-primed dendritic cells and Ursolic acid-
primed dendritic cells, and induced T cell differentiation towards Th2. IL-10 can promote 
Th2 responses that may be inhibitory for Th1 responses and negatively influences the ability 
of the differentiation of dendritic cells from human monocytes to produce IL-12p70. IL-10 
might play a key role in the Th1/Th2 response by inhibiting IL-12p70. Therefore, our results 
suggest that the development of the Th1/2 response, at least in part, is controlled by the 
production of IL-12p70 via TLR2 and/or TLR4 signaling on dendritic cells. URC-primed 
dendritic cells and Ursolic acid-primed dendritic cells provide stronger costimulatory 
signals and/or the proinflammatory cytokines needed for T cell activation depending on 
TLR2 and/or TLR4, and induced Th1 development. 
 
 
Fig. 4. URC induces NF-B activation and modulates TLR2 and TLR4. (A) DC were 
stimulated with URC (0.5 M), LPS (100 ng/ml) or medium for 30 min, 1 h. and 2 h., and 
nuclear extracts were analyzed for their NF-B binding activity using EMSA. 1: Competition 
(x 100 cold) negative control 2: immature dendritic cells (0 min), 3: immature dendritic cells 
(30 min) 4: immature dendritic cells (1 h) 5: immature dendritic cells (2 h) 6: LPS (0 min) 7: 
LPS (30 min) 8: LPS (1 h) 9: LPS (2 h) 10: URC (0 min) 11: URC (30 min) 12: URC (1 h) 13: 
URC (2 h). (B) Relative TLR expression during the differentiation of dendritic cells. 
Monocytes were cultured with GM-CSF and IL-4 to differentiate to immature dendritic cells 
for 8 days. Maturation of dendritic cells was induced by URC (0.1 M), Ursolic acid (1 M) 
or LPS (1 g/ml). Cells were collected at indicated time; mRNA were extracted and 
converted to cDNA. The cDNA were subjected to Realtime SYBR Green quantitative PCR 
using gene-specific primers pair for TLR2, TLR4 and -actin. Relative gene expression was 
calculated using 2-ΔΔCt method. Left panel: Relative TLR4 expression during differentiation 
of dendritic cells by LPS in comparison to stimulation of dendritic cells with URC or Ursolic 
acid. Right panel: Relative TLR2 expression during differentiation of DC by LPS in 
comparison to stimulation of dendritic cells with URC or Ursolic acid. Data are the mean  
S.E.M. of three independent experiments. *P< 0.05 compared with immature dendritic cells 
(iDC). 
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2.3 URC-primed dendritic cells and Ursolic acid-primed dendritic cells promote the 
differentiation of naïve T cells into Th1 cells  
Given that the nature of cytokines secreted by dendritic cells are known to govern the type 
of T response observed, we evaluated the nature of primary allogeneic T cell responses 
stimulated by URC-primed dendritic cells and Ursolic acid-primed dendritic cells. 
Allogeneic URC-, Ursolic acid-, LPS- or TNF--primed dendritic cells induced as substantial 
increase in the secretion of IFN- by T cells (Fig.5A), but had little effect on IL-4 secretion 
(Fig.5B). Very consistently, the production of IL-4 and IL-10 are coherently dependent on the 
factors used to drive dendritic cells-maturation. In contrast, the production of IFN- and IL-4 
induced by naïve T cells co-cultured with immature dendritic cells was low (Fig.5A and B). 
This Th1 response was confirmed by flow cytometry (data not shown).  
 
Fig. 5. Effect of anti-IL-12 mAb on polarization of naïve T cells by dendritic cells. Dendritic 
cells were co-cultured with naïve T cells days in the presence of control Ab or anti-IL-12 
mAb (10 g/ml). After 9 days of expansion in IL-2, T cells were counted and re-stimulated 
for 24 h with Dynabeads CD3/CD28. After 24 h, IFN- (A) or IL-4 (B) was measured by 
ELISA in culture supernatants. iDC: immature dendritic cells. Data are the mean  S.E.M. of 
five independent experiments. *P< 0.05 compared without mAb. 
To analyze the contribution of dendritic cells-derived IL-12p70 on the development of Th1 
cells, we tested the effect of a neutralizing anti-IL-12 mAb in co-cultures of dendritic cells 
with naïve T cells. In naïve T cells co-cultured with URC-, Ursolic acid-, LPS- or TNF--
primed dendritic cells, neutralization of IL-12 increased the development of IL-4 producing 
T cells and dramatically decreased the development of IFN- producing T cells (Fig.5A and 
B). In contrast, the production of IFN- and IL-4 by naïve T cells co-cultured with URC-, 
Ursolic acid-, LPS- or TNF--primed dendritic cells was not influenced when IgG1 was used 
instead of anti-IL-12 mAb (Fig.5A and B). Even higher production of IFN- by T cells was 
induced by dendritic cells matured with URC in the presence of IFN- (data not shown). 
Anti-IL-12 neutralizing Abs decreased IFN- secretion, confirming both the presence of 
bioactive IL-12 and its direct role in IFN- induction in this culture system. Th1 and Th2 
development depend on the route of immunization, the nature and the concentration of Ag 
and the balance between IL-4 and IL-12 at priming. Our data showed that LPS-, URC- or 
Ursolic acid-primed dendritic cells polarized T cells into Th1 via high IL-12p70 secretion 
upon CD40-L (T cells engagement) stimulation and demonstrated that the production of 
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IFN- by naïve T cells co-cultured with URC-primed dendritic cells and Ursolic acid-primed 
dendritic cells was affected by the presence of a neutralizing anti-IL-12 mAb. The 
production of IL-12p70 by dendritic cells is a major inducer of IFN-. The reduced induction 
of IFN- after incubation with anti-IL-12 mAb indicates that IFN- induction is largely 
dependent on endogenous IL-12. Therefore, the data suggest that the effect of URC and 
Ursolic acid on the production of IL-12p70 by dendritic cells and strengthening of the Th1 
response by naïve T cells might contribute to a potential antitumor effect of URC and 
Ursolic acid. The rational for selecting IL-12 production as a potency assay for dendritic cells 
generated for human therapy is based on IL-12 properties, and its confirmed role in host 
defense against pathogens and cancer. The generation of effective antitumor immunity 
involves the production of Th1 cytokines such as IL-12 and IFN- that might facilitate the 
induction and/or activation of tumor Ag-specific CD4 and CD8 cells. IL-12p70 is the 
cytokine responsible for antitumor responses of T lymphocytes. The understanding of 
mechanism controlling IL-12 induction by adjuvant in general and URC and Ursolic acid, in 
particular, may contribute to improving cellular immune responses in human therapies. It 
seems that TNF--primed dendritic cells drive the differentiation of naïve T cells towards 
Th1 cells via an unknown factor, because TNF--primed dendritic cells did not increase the 
IL-12 production upon adding CD40-L.  
2.4 Cytotoxicity of CD8+T cells against T2 target cells 
Dendritic cells are professional APC that are required for the initiation of immune 
responses. In the immunotherapy against malignant diseases, it has been suggested that the 
induction of tumor antigen-specific CTL is most important for eliminating tumor cells. 
Antitumor immunity has classically been measured by the quantity of tumor-antigen-
specific CD8+ T cells. In this context, it is important to know whether URC-primed dendritic 
cells and Ursolic acid-primed dendritic cells enhanced specific CTL responses. We 
compared the CTL responses of autologus CD8+T cells supported by dendritic cells 
differentiated with URC or TNF-. In an 8 h. to measure CTL apoptosis by tumor cells, T2 
cells loaded with WT-1 peptides strongly induced DNA fragmentation of CTL that were 
generated with URC-primed dendritic cells pulsed with WT-1 peptides (Fig.6A). Details of 
the method used in these assay have been described previously (Takei et al. 2004, Mailliard 
and Lotz 2001, Nakano et al. 1998). As expected from their Th-1-polarizing effect, percentage 
of DNA fragmentation was dependent on the increased number of CTL cells. Similar results 
were obtained with a 51Cr release assay to measure lysis of target cells (Fig.6B). URC-primed 
dendritic cells induced a stronger CTL response than immature dendritic cells or TNF--
primed dendritic cells. On the other hand, percentage of DNA fragmentation in JAM assay 
and 51Cr release were low or undetectable when T2 loaded with HIV-1 peptide (unrelated 
peptide) and T2 (without peptides) were used as the target cells (negative control) (Fig.6A 
and B). Dendritic cells activated with TLR agonists, especially TLR4 and TLR8 agonists 
stimulate IL-12-producing human myeloid dendritic cells, which activate CD8 CTL against 
tumors. Moreover, Kawasaki et al. (2000) have reported that TLR4 mediates LPS-mimetic 
signal transduction by anti-cancer agents Taxol, a plant-derived diterpene, in mice but not 
human. More recently, synthetic ligands for TLR4, TLR7 or TLR9 have been through 
preclinical evaluation and clinical trials against cancer. Therefore, that suggests that URC 
might be a promising agent for the treatment of cancer. The effects of dendritic cells 
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matured with Ursolic acid in the CTL responses are not known yet. However, we expect to 
obtain similar results with URC-primed dendritic cells, because dendritic cells matured with 
Ursolica cid enhanced the differentiation of naïve T cells towards the Th1 type. 
 
Fig. 6. Autologus CD8+T cells incubated with URC-primed dendritic cells showed higher 
cytolytic activity against T2 target cells loaded with WT-1 peptide at a high effector-to-target 
ratio than against T2 target cell without WT-1 peptide. (A) The CTL were labeled with [3H]-
methylthymidine and served as the target for tumor cell lines. T2 cells induced more DNA 
fragmentation of CTL that were generated with URC-primed dendritic cells pulsed with 
WT-1 peptides than those that were generated with immature dendritic cells or TNF--
primed DC pulsed with WT-1 peptides. (B) Specific lysis was measured by 51Cr release 
assay. Data are the mean  S.E.M. of three independent experiments. *P< 0.05 compared 
with T2. 
2.5 URC-primed dendritic cells and Ursolic acid-primed dendritic cells are capable of 
migration in vitro 
The ability of dendritic cells to migrate to local lymph nodes and their subsequent 
presentation of antigen to T cells play an essential role in the initiation of adaptive 
immunity. In tissues, mature dendritic cells must be responsive to lymph node derived 
signals, but must also be able to down-regulate tissue anchoring proteins including E-
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cadherin that would otherwise detrimental dendritic cells migration and antigen 
presentation to naïve T cells. Migration to the secondary lymphoid organs and subsequent 
antigen presentation requires dendritic cells maturation, a process that is associated with 
up-regulation of co-stimulatory molecules. We investigated the migratory capacity of URC-
primed dendritic cells and Ursolic acid-primed dendritic cells toward CCL19 and CCL21. 
URC-primed dendritic cells and Ursolic acid-primed dendritic cells had migration in 
response to CCL19 and CCL21 (Fig.7), and slightly up-regulated the expression of CCR7 and 
CD38 on URC-primed dendritic cells and Ursolic acid-primed dendritic cells (Fig.1). 
Expression of CCR7 seems also to be important for other aspects of dendritic cells biology, 
in particular in enhancing chemotaxis and trans-endothelial passage in response to CCL19 
and CCL21. Recently, it has been reported that expression of CD38 on dendritic cells is 
essential for their coordinated migration to the T cell area of draining lymph node and 
increase dendritic cells function (Trepiakas et al. 2009). These results suggest that URC-
primed dendritic cells and Ursolic acid-primed dendritic cells migrate in vivo and is a 
promising approach for the treatment of cancer. In most clinical trials using dendritic cells-
based immunotherapy, immature monocyte-derived dendritic cells pulsed with tumor 
antigen peptides were used. Recent studies showed that mature dendritic cells could be a 
better antitumor adjuvant. However, there is no clear answer yet. 
 
Fig. 7. Chemotaxis in response to CCL19 and CCL21 by URC-, Ursolic acid-, LPS- or TNF--
primed dendritic cells. URC-, Ursolic acid-, LPS- or TNF--primed dendritic cells were 
prepared and recovered, and their migratory abilities in response to CCL19 (500 ng/ml) and 
CCL21 (500 ng/ml) were determined in vitro. Data are the mean  S.E.M. of three 
independent experiments. *P< 0.05 compared with immature dendritic cells (iDC). 
3. In conclusion 
We described in this chapter a very promising and cost effective dendritic cells maturation 
factor consisting of URC and Ursolic acid, both mature dendritic cells which meet the 
dendritic cells criteria important for efficient immunotherapy, including the capacity to 
migrate and the production of IL-12p70 upon CD40 triggering. Although based on in vitro 
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results, URC and Ursolica cid may be used in dendritic cells-based vaccine for cancer 
immunotherapy. Several mechanisms have been proposed to explain the apparent adjuvant 
effects of TLR agonists on atitumor immunity. TLR trigger the secretion of critical cytokines, 
and TLR can stimulate the proliferation of CD4+ T cells and CD8+ T cells. Moreover, TLR 
signaling frequently enhances the production of IL-12 in dendritic cells. Thus, it is strongly 
suggested that dendritic cells matured with TLR stimulation may induce T cell 
differentiation toward Th1 by presenting antigens to T cells while promoting a Th1-leading 
situation in the local environment. Several TLR agonists have been developed as anticancer 
drugs. We expect to be able to correlate the in vitro dendritic cells product attributes with in 
vivo immunologic and clinical end point. 
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